Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
DOI:
https://doi.org/10.53778/pjkd40353الكلمات المفتاحية:
Rejection, kidney transplant، acute rejection، chronic rejection، antibody mediated rejection، complement,، plasmapheresis، Bortezomib,، Rituximab، Eculizumab، Tocilizumabالملخص
Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.
التنزيلات
منشور
2021-01-31
إصدار
القسم
Review Article
الرخصة
الحقوق الفكرية (c) 2021 Salman Tahir Shafi
هذا العمل مرخص بموجب Creative Commons Attribution-NonCommercial 4.0 International License.
كيفية الاقتباس
Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353
